ciglitazone has been researched along with belinostat in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Arnason, TG; Davies, GF; Harkness, TA; Juurlink, BH; Ross, AR | 1 |
1 other study(ies) available for ciglitazone and belinostat
Article | Year |
---|---|
Troglitazone inhibits histone deacetylase activity in breast cancer cells.
Topics: Acetylation; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Butyrates; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromans; Dose-Response Relationship, Drug; Epigenesis, Genetic; Female; Histone Deacetylase 1; Histone Deacetylase 2; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Hydroxamic Acids; Methylation; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Binding; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Receptors, Estrogen; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Sulfonamides; Thiazolidinediones; Troglitazone | 2010 |